Skip to main content

View full-text article in PMC

. 2016 Aug 8;12(4):2648–2656. doi: 10.3892/ol.2016.4969

Table II.

Univariate prognostic analysis of overall and disease-free survival rates in patients with hepatocellular carcinoma.

		Overall survival rate			Disease-free survival rate

Variable	n	3-year, %	5-year, %	P-value	3-year, %	5-year, %	P-value
Gender				0.891			0.895
Female	18	82.4	51.0		82.4	44.9
Male	56	78.2	50.1		74.6	44.5
Age, years				0.644			0.732
≤45	17	81.3	68.8		75.6	56.7
>45	57	78.6	44.7		76.8	41.1
HBsAg status				0.079			0.073
Negative	6	50.0	33.3		50.0	33.3
Positive	68	81.9	52.0		78.9	45.7
Cirrhosis				0.235			0.318
No	12	66.7	50.0		66.7	50.0
Yes	62	81.8	50.4		78.5	43.5
AFP, µg/l				0.122			0.224
≤400	29	68.1	41.0		64.7	33.2
>400	45	86.4	56.3		84.1	51.8
Tumor size, cm				0.764			0.778
≤5	26	60.1	47.5		60.4	47.7
>5	48	89.4	52.0		85.2	47.8
Tumor number				<0.001^a			<0.001^a
Single	47	95.7	58.3		93.6	56.3
Multiple	27	48.4	36.3		44.9	23.0
Tumor capsule				0.739			0.715
Complete	52	76.5	44.0		72.6	44.3
Incomplete	22	85.7	66.0		85.7	45.7
Vascular infiltration				0.035^a			0.049^a
No	54	92.4	54.1		90.5	50.2
Yes	20	45.0	40.0		45.0	30.0
Edmondson grade				<0.001^a			<0.001^a
I/II	48	93.7	56.4		93.7	54.5
III/IV	26	46.3	37.9		42.6	25.6
TNM Stage				0.020^a			0.027^a
I/II	45	93.3	54.1		91.1	47.3
III/IV	29	48.5	40.7		45.2	32.9
BCAT1 protein level				0.004^a			0.004^a
Low	37	94.6	66.8		94.6	58.5
High	37	60.3	33.2		57.7	30.5

^a

P<0.05. HbsAg, hepatitis B surface antigen; BCAT1, branched-chain amino acid transaminase 1; TNM, tumor-node-metastasis; AFP, α-fetoprotein.